NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.
|Articles|January 1, 2015
- BioPharm International-01-01-2015
- Volume 28
- Issue 1
Aseptic Robot Decreases Cycle Time
Advertisement
Denso Robotics’ VS-050 aseptic robot is a six axis-machine with an ISO 5 cleanroom rating for biocontamination control. The robot is designed with a protective outer coating and sealed joints for decontamination purposes. Free from external screws or wires, the control-cable connector is located on the bottom of the robot to allow for easy cleaning and streamlining.
With an overall arm length of 520 mm and a maximum composite speed of 9690 mm/sec, the robot is available with payloads up to 4 kg, a reach of 520 mm, and repeatability of ±0.02 mm. The VS-050 robots are designed for applications such as assembly, dispensing, inspection, machine tending, material handling, packaging, and test handling. The compact design is ideal for small work spaces.
Denso Robotics
Articles in this issue
over 11 years ago
Great Expectations from New European Commissionover 11 years ago
Analyzing Protein Aggregation in Biopharmaceuticalsover 11 years ago
Raw Materials and the Development Cycleover 11 years ago
Fill/Finish Capacity Use for Biologicsover 11 years ago
Politics and Patients to Shape Pharma in 2015over 11 years ago
Standards Organizations Updateover 11 years ago
Adopting the Product Lifecycle Approachover 11 years ago
Ligand-Binding Assays and the Determination of Biosimilarityover 11 years ago
Drug Breakthroughs, with Some Reservationsover 11 years ago
Technologies and Practices Must Evolve to Meet DemandAdvertisement
Related to this article
Updated 36-month data in 15 high-dose patients showed 80% slowing on cUHDRS, while the 48-month cUHDRS result did not reach statistical significance. uniQure attributes the gap to attrition in the external control, and the FDA is reviewing a BLA based on the 36-month data.
Guselkumab eased spinal pain, stiffness, and MRI-confirmed spinal inflammation in a 411-patient trial of psoriatic arthritis with axial involvement.
Dr Stephen Wilson, CEO of the Botnar Institute of Immune Engineering, describes Basel's collaborative ecosystem and a 3-year roadmap linking research to global clinical partners.
BIIE CEO Dr Stephen Wilson outlines rapid growth plans and a multidisciplinary technology stack targeting global clinical translation.
Dazodalibep hit its phase 3 primary endpoint at week 48, building on phase 2 data showing a 6.3-point ESSDAI reduction versus placebo.
Made Scientific's new 85,000-sq.-ft. facility, with 145 prior GMP batches, adds clinical- to commercial-scale cell therapy capacity.
Novo Nordisk reports that CagriSema outperformed tirzepatide with 12.4% weight loss versus 9.1% in a phase 3 trial in adults with type 2 diabetes.
Advertisement
Advertisement